ARTICLE | Company News
Precision Therapeutics, Rosetta Genomics sales and marketing update
April 15, 2013 7:00 AM UTC
Rosetta and Precision launched the miRview mets2 assay in the U.S. to identify the primary origin of tumor of uncertain or unknown origin. miRview mets2 is a microRNA-based test that identifies the primary origin of 42 different tumor types. Precision has co-commercialization rights in the U.S. to miRview mets2 from Rosetta (see BioCentury, July 30). ...